We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Cohbar Inc (CWBR) USD0.001

Sell:$0.45 Buy:$0.48 Change: $0.0192 (4.06%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
Change: $0.0192 (4.06%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
Change: $0.0192 (4.06%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

CohBar, Inc. (CohBar) is a clinical-stage biotechnology company. The Company is focused on the research and development of mitochondria based therapeutics (MBTs), an emerging class of drugs for the treatment of chronic and age-related diseases. The Company’s lead compound, CB4211, is in the Phase I b stage of a Phase I a/1b clinical trial for nonalcoholic steatohepatitis (NASH) and obesity. In addition, CohBar has four preclinical programs, including one in fibrotic diseases, one in acute respiratory distress syndrome (ARDS) and two in cancer. The Company’s pipeline is focused on identifying, assessing and optimizing new analogs of biologically active MDPs. Its pipeline includes peptide analogs of mitochondrial-derived peptides (MDPs) in different stages of research evaluation as potential MBTs, and one MBT in clinical development.

Contact details

1455 Adams Dr Ste 2050
United States
+1 (650) 4467888

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$40.06 million
Shares in issue:
86.06 million
United States
US dollar

Key personnel

  • Joseph Sarret
    Chief Executive Officer, Director
  • Jeffrey Biunno
    Chief Financial Officer, Treasurer, Secretary
  • Kenneth Cundy
    Chief Scientific Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.